AffyMax Overview

  • Founded
  • 2001

Founded
  • Status
  • Public

  • Employees
  • 72

Employees
  • Stock Symbol
  • AFFY

Stock Symbol

AffyMax General Information

Description

Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Contact Information

Website
www.affymax.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
PINX
Primary Office
  • 600 Fifth Avenue
  • 2nd Floor
  • New York, NY 10020
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AffyMax Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
24.7K

AffyMax Financials Summary

In Thousands,
USD
TTM 30-Jun-2014 FY 2013 31-Dec-2013 FY 2012 31-Dec-2012 FY 2011 31-Dec-2011
EV (1,051) 22,390 636,650 120,931
Revenue 42 1,369 94,370 47,720
EBITDA 2,694 (14,316) (90,086) (59,209)
Net Income 2,694 (14,424) (93,412) (61,367)
Total Assets 5,384 7,443 118,217 118,995
Total Debt 0 0 8,844 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AffyMax Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AffyMax‘s full profile, request access.

Request a free trial

AffyMax Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for
Pharmaceuticals
New York, NY
72 As of 2015
00000
000000000 00000

000000

commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu
0000 000000000
New York, NY
0 As of 0000
00000
0000000000 00000

0000

on ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit i
0000 000000000
San Diego, CA
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AffyMax Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Akelos (Drug Discovery) Angel-Backed New York, NY 0 00000 0000000000 00000
0000 Venture Capital-Backed San Diego, CA 00 00000 00000000000 00000
0000000 0000000000 Venture Capital-Backed South San Francisco, CA 00 000.00 00000000000 000.00
0000 000000000000 Formerly VC-backed Waltham, MA 00 00000 00000000 00000
0000000 Formerly VC-backed Leuven, Belgium 00 00000 000000&0 00000
You’re viewing 5 of 13 competitors. Get the full list »

AffyMax Patents

AffyMax Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20090209457-A1 Treatment of anti-erythropoietin antibody-mediated disorders with synthetic peptide-based epo receptor agonists Abandoned 15-Feb-2008 000000000
JP-2009191056-A Therapy of disorder mediated by anti-erythropoietin antibody using epo receptor agonist based on synthetic peptide Pending 15-Feb-2008 000000000
US-20090124709-A1 Analytical methods for validating excipient purity Abandoned 10-Sep-2007 000000000
US-20090042802-A1 Compounds and peptides that bind the kgf receptor Abandoned 22-Jun-2007 000000000
US-20090131317-A1 Compounds and peptides that bind the trail receptor Abandoned 22-Jun-2007 C07K14/70575 00
To view AffyMax’s complete patent history, request access »

AffyMax Executive Team (28)

Name Title Board Seat Contact Info
Richard Brenner Chief Executive Officer & Board Member
J. Rose President
Mark Thompson Chief Financial Officer, Finance
Grace Shin JD General Counsel
Christine Conroy Senior Vice President, Regulatory Affairs and Quality Assurance
You’re viewing 5 of 28 executive team members. Get the full list »

AffyMax Board Members (17)

Name Representing Role Since
Christine van Heek Self Board Member 000 0000
Hollings Renton Self Chairman & Board Member 000 0000
John Orwin Self Board Member 000 0000
John Walker Self Board Member 000 0000
Richard Brenner AffyMax Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 17 board members. Get the full list »

AffyMax Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AffyMax Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore AffyMax‘s full profile, request access.

Request a free trial